The aim of this study was to identify the effects of cyclooxygenase (COX)-1 and -2
inhibition each on insulin sensitivity in healthy subjects. A randomized, double-blind,
controlled clinical trial was carried out in 21 young, healthy, non-obese male volunteers.
Pharmacological COX-1 inhibition was performed with the prescription of acetylsalicylic
acid (ASA) at a low dose, and COX-2 selective inhibition was performed with celecoxib.
After randomization, all subjects received an oral morning dose of ASA 100 mg (n =
7), celecoxib 200 mg (n = 7), or placebo for the control group (n = 7) during a period
of 15 days. Before and after of the study period, a metabolic profile was measured
in all participants. An insulin tolerance test (ITT) was performed to assess insulin
sensitivity, and the constant for the serum glucose disappearance rate (K ITT) was
calculated. Clinical and metabolic characteristics were similar between groups. The
K ITT calculated with the ITT was higher after celecoxib than at baseline (4.8 ± 0.9
vs. 4.3 ± 0.6 %/min, p = 0.04), indicating improvement in insulin sensitivity. Neither
ASA nor placebo administrations modified insulin sensitivity. In conclusion, COX-2-selective
inhibitor at a celecoxib dose of 200 mg daily increased insulin sensitivity in healthy
subjects.
Key words:
Cyclooxygenase-1 - Cyclooxygenase-2 - Insulin Sensitivity - Insulin Action - COX -
Insulin Tolerance Test
References
- 1
Jouzeau J -Y, Terlain B, Abid A, Nédélec E, Netter P.
Cyclooxygenase isoenzymes.
Drug.
1977;
53
563-582
- 2
Lipsky P E, Abramson S B, Crofford L, Dubois R N, Simon L S, Van de Putte L BA.
The classification of cyclooxygenase inhibitors.
J Rheumatol.
1998;
25
2298-2303
- 3
Newsholme E A.
Some experiments on factors that can change insulin sensitivity.
Ann Med.
1990;
22
181-184
- 4
Leighton B, Chaliss R AJ, Newsholme E A.
The role of prostaglandins as modulators of insulin-stimulated glucose metabolism
in skeletal muscle.
Horm Metab Res.
1990;
22 (Suppl.)
89-95
- 5
Wasner H K, Weber S, Partke H J, Amini-Hadi-Kiashar H.
Indomethacin treatment causes loss of insulin action in rats: involvement of prostaglandins
in the mechanism of insulin action.
Acta Diabetol.
1994;
31
175-182
- 6
Paolisso G, Gambardella A, Saccomanno F, Varricchio G, D'Amore A, Varricchio M.
Low-dose iloprost infusion improves insulin action and non-oxidative glucose metabolism
in hypertensive patients.
Eur J Clin Pharmacol.
1995;
48
333-338
- 7
González-Ortiz M, Martínez-Abundis E, Escalante-Pulido J M.
Comparison of homeostasis model analysis with insulin tolerance test in the assessment
of insulin resistance in healthy young people.
Diab Nutr Metab.
1998;
11
136-139
- 8
Summers S A, Yin V P, Whiteman E L, Garza L A, Cho H, Tuttle R L, Birnbaum M J.
Signaling pathways mediating insulin-stimulated glucose transport.
Ann N Y Acad Sci.
1999;
892
69-186
- 9
Robertson P.
Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin
synthesis.
Diabetes.
1998;
47
379-1383
- 10
Meade E A, Smith W L, DeWitt D L.
Diferential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes
by aspirin and other non-steroidal anti-inflammatory drugs.
J Biol Chem.
1993;
268
6610-6614
- 11
Green A, Walters D J, Belt S E.
Insulin resistance in adipocytes after downregulation of Gi subtypes.
Am J Physiol.
1997;
273
E254-E261
- 12
Virkamäki A, Yki-Järvinen H.
Role of prostaglandins in mediating alterations in glucose metabolism during acute
endotoxemia in the rat.
Endocrinology.
1995;
136
701-1706
- 13
Salazar-Páramo M, González-Ortiz M, González-López L, Sánchez-Ortiz A, Valera-González I C,
Martínez-Abundis E, Balcázar-Muñoz B R, García-González A, Gámez-Nava J I.
Serum leptin levels in patients with rheumatoid arthritis.
J Clin Rheumatol.
2001;
7
57-60
- 14
González-Ortiz M, Martínez-Abundis E, Pascoe-González S.
Comparison between usual and low doses of insulin in the assessment of insulin sensitivity
with a short insulin tolerance test in obese women.
Arch Med Res.
1999;
30
385-387
- 15
Suzuki M, Ikebuchi M, Shinozaki K, Hara Y, Tsushima M, Matsuyama T, Harano Y.
Mechanism and clinical implication of insulin resistance syndrome.
Diabetes.
1996;
45 (Suppl. 3)
S52-S54
M. González-Ortiz,M.D., M.Sc.,Ph.D.
Montes Urales 1409
Colonia Independencia
44340, Guadalajara
México
Phone: Phone:+ 52 (3) 826-7022
Fax: Fax:+ 52 (3) 616-1218
Email: E-mail:uiec@prodigy.net.mx